The summa of ZUMA: Lessons from a decade of CD19-targeted CAR-T trials in B-cell malignancies.
文献摘要
Background The ZUMA program established the CD19-directed CAR-T therapies axicabtagene ciloleucel (axi-cel) and brexucabtagene autoleucel (brexu-cel) as effective treatments for relapsed/refractory B-cell malignancies, producing high response rates and durable remissions. Methods We conducted a translational narrative review of ZUMA publications through April 2026 (PubMed, Cochrane Library, ClinicalTrials.gov). We extracted study design, patient characteristics, efficacy outcomes (ORR, CR, PFS, EFS, OS, DOR, MRD negativity), and safety outcomes (CRS, ICANS, hematologic toxicity). Results Fifteen ZUMA trials enrolled more than 1100 patients with aggressive and indolent B-cell lymphomas and B-cell acute lymphoblastic leukemia (B-ALL). In large B-cell lymphoma, ZUMA-1 reported 5-year OS of 42.6% and PFS of 31.8%. ZUMA-7 showed that axi-cel was superior to second-line standard of care (median EFS 8.3 vs. 2.0 months). ZUMA-12 supported first-line use in high-risk disease (CR 86%; median PFS not reached at the 3-years analysis). In mantle cell lymphoma, ZUMA-2 achieved an ORR of 91-93%, with remissions beyond 3 years. In adult B-ALL, ZUMA-3 reported a CR/CRi rate of 71%, MRD negativity in 97% of responders, and a median OS of 25.6 months. In follicular lymphoma, ZUMA-5 reported a median PFS of 57.3 months. Early CAR-T expansion correlated with depth of response. CRS and ICANS were the main acute toxicities, and prolonged cytopenias were the most relevant late toxicity. Combination strategies (ZUMA-6, -11, -14, -19) remain largely exploratory. Conclusions ZUMA data establish CD19-directed CAR-T therapy as a transformative, potentially curative strategy in B-cell malignancies. Earlier integration into treatment sequencing, optimized T-cell fitness, cytokine modulation, and microenvironment-targeted combinations may further improve long-term outcomes.